NeoGenomics backs FY24 revenue view $655M-$667M, consensus $662M

Backs FY24 adjusted EBITDA view $37M-$40M. The company said, “The Company has reaffirmed its full-year 2024 guidance, originally issued on November 5, 2024. For the year ended December 31, 2024, consolidated revenue is expected to be in the range of $655 to $667 million. Net loss is expected to be in the range of $(81) to $(78) million. Adjusted EBITDA is expected to be in the range of $37 to $40 million.”